May 14, 2026
China’s Pharmaceutical Weapon
This article was originally published in The National Interest.
This week’s Donald Trump–Xi Jinping summit in Beijing will not lack for contested business. Iran, Taiwan, AI, tariffs, and critical minerals will each compete for time on the agenda, and each will dominate the post-summit coverage. One item less likely to get airtime, however, is one with a direct impact on American lives: the dependence of the US pharmaceutical and biotechnology sector on Chinese inputs, and the leverage that dependence already hands Beijing.
Until SAPIR is extended to biologically derived drugs, until the FDA clears the bovine pathway, and until at least one American-owned heparin manufacturer operates on US soil, every dialysis shift in this country proceeds on the assumption that Beijing will not exercise leverage it already holds.
Heparin is the cleanest illustration. The drug is the blood thinner of record across American medicine—present in nearly every hemodialysis session, every major cardiac procedure, the standard treatment for deep-vein thrombosis and pulmonary embolism, and routine ICU protocols. Most of the US dialysis population—roughly 550,000 patients—have no clinical substitute available to them. The raw material is porcine intestinal mucosa, collected from thousands of small village workshops concentrated in China’s Shandong Province.
Read the full article in The National Interest.
More from CNAS
-
Does the Quad Still Matter?
Commentary
Under the second Trump administration, some analysts have expressed growing pessimism about the group’s effectiveness, given the president’s apparent lack of interest in atten...
By Lisa Curtis
-
Thwarting Communications Blackout
Reports
Executive Summary Control over the physical means of transmitting information—the lifeblood of modern societies—has become a central area of contestation between Taiwan and th...
By Jacob Stokes & Ryan Claffey
-
Pakistan’s Growing Regional Role
Video
Pakistan’s regional role is expanding — but what does it mean for the Middle East, the United States, and the Indo-Pacific? In a new MBN Digital Salon, Jeffrey Gedmin discusse...
By Lisa Curtis
-
Japan’s Point of No Return
Commentary
But if Washington treats a stronger Japan as a true partner and keeps it firmly within its alliance system, American influence in Asia will be greater than ever....
By Daisuke Kawai
